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Summary
We have investigated the role of the Rho/ROCK signaling pathway in the interaction of metastatic melanoma
cells with the brain endothelium. ROCK inhibition induced a shift of melanoma cells to the mesenchymal
phenotype, increased the number of melanoma cells attached to the brain endothelium, and strengthened the
adhesion force between melanoma and endothelial cells. Inhibition of ROCK raised the number of melanoma
cells migrating through the brain endothelial monolayer and promoted the formation of parenchymal brain
metastases in vivo. We have shown that inhibition of the Rho/ROCK pathway in melanoma, but not in brain
endothelial cells, is responsible for this phenomenon. Our results indicate that the mesenchymal type of tumor
cell movement is primordial in the transmigration of melanoma cells through the blood–brain barrier.
Introduction
Brain tumors are life-threatening pathologies with limited
therapeutic options, representing a major cause of death
in patients with cancer. The majority of the tumors of the
central nervous system (CNS) are metastases, among
which lung cancer, breast cancer, and melanoma are the
most common. Melanoma has an unexpectedly high
affinity to the brain, the prevalence of brain metastases
being 55–75% in patients with melanoma. Unfortunately,
present treatment strategies of melanoma brain metas-
tases are very ineffective, the prognosis of the disease is
extremely poor: The median survival of the patients is
< 1 yr (reviewed in: Chen and Davies (2012)). Therefore,
development of strategies aiming to prevent the dissem-
ination of melanoma cells into the CNS is urgently
needed. This requires understanding of the mechanisms
of melanoma brain metastasis formation, in particular
identification of key pathways and molecules involved in
the interplay between melanoma cells and cells of the
CNS.
The first host cell type encountered by circulating
cancer cells during brain metastasis formation is endo-
thelial cells of the brain vasculature. Cerebral endothelial
cells (CECs) have a highly differentiated phenotype,
induced and maintained by the cross-talk with the
Significance
The first host cells encountered by melanoma cells during brain metastasis formation are cerebral
endothelial cells, which form the morphological basis of the blood–brain barrier (BBB). Despite the
undisputable clinical importance, little is known about the mechanisms of extravasation of melanoma cells
through the BBB. Our data suggest that the mesenchymal type of tumor cell movement (induced by ROCK
inhibition) is more important than the ameboid type during migration of melanoma cells through the brain
endothelium. This mechanism might have clinical importance as well, as pharmacological inhibitors of
ROCK signaling are emerging as potent therapeutic agents in different pathologies.
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surrounding cells of the neurovascular unit. In this
respect, CECs have special epithelial-like features, includ-
ing the formation of a continuous belt of tight junctions
between cells and expression of a special set of trans-
porters and enzymes, which result in the formation of the
blood–brain barrier (BBB) (for review see: Abbott et al.
(2010); Wilhelm et al. (2011)). Therefore, during extrava-
sation from the blood stream into the brain parenchyma,
melanoma cells have to migrate through the BBB.
Nevertheless, the interactions between melanoma cells
and endothelium of the CNS are still largely uncharacter-
ized (reviewed in: Wilhelm et al. (2013)).
Rho-kinases (ROCK1 and ROCK2) are the main effec-
tors of the small GTPase RhoA and RhoC, having several
substrates (including the LIM-kinases and myosin light
chain) involved in the regulation of the cytoskeleton.
Accordingly, the Rho/ROCK pathway plays important
roles in a wide range of cellular phenomena, such as
contractility, motility, cell cycle, apoptosis, or intercellular
adhesion.
Rho/ROCK signaling was shown to be involved in the
ameboid invasion phenotype of cancer cells, which is
characterized by rounded morphology and increased
actomyosin contractility. Nevertheless, tumor cells are
able to switch between the ameboid and mesenchymal
type of cell movement, and this latter displaying an
elongated morphology, extracellular proteolysis, and
activation of the small GTPase Rac (Sahai and Marshall,
2003; Sanz-Moreno et al., 2008; Wolf et al., 2003). It is
not surprising that studies regarding the effects of
ROCK inhibition on tumor cell motility, invasion, and
metastasis formation are contradictory and appear to
depend on the tumor cell type. Inhibition of ROCKs has
been shown to decrease the invasion and migration of
lung (Yang et al., 2010, 2012; Zhu et al., 2011), breast
(Wyckoff et al., 2006), and hepatocellular carcinoma
cells (Chen et al., 2011; Itoh et al., 1999; Ying et al.,
2006). In contrast, in case of osteosarcoma (Yui et al.,
2010), pancreatic carcinoma (Fujita et al., 2011), colon
carcinoma (Adachi et al., 2011; Vishnubhotla et al.,
2012), and scirrhous gastric carcinoma (Matsuoka et al.,
2011), ROCK inhibitors promoted invasive and migratory
properties of the cells. Regarding melanoma, inhibition
of the Rho/ROCK signaling system was shown to alter
the expression of tumor progression genes (Spencer
et al., 2011), reduce proliferation (Routhier et al., 2010),
cell invasion, and formation of lung metastases (Kidera
et al., 2010).
In addition, movement of tumor cells might also
depend on the physicochemical and biological proper-
ties of the extracellular matrix or endothelial barrier they
need to cross. For example, a thick soft three-dimen-
sional substratum was shown to favor ameboid type of
tumor cell migration, while cells with mesenchymal
phenotype prefer a firm two-dimensional substratum
(Symons and Segall, 2009). Moreover, the Rho/ROCK
pathway in both the tumor and endothelial cells is likely
to play a role in the transendothelial migration. There-
fore, ROCK inhibitors might influence (additively or
oppositely) this process from the side of both cell
types.
Considering the controversial role of Rho/ROCK signal-
ing in cancer biology, and the clinical importance of
melanoma brain metastases, we have investigated the
potential role of the Rho/ROCK pathway in the interaction
of melanoma and cerebral endothelial cells.
Results
Role of Rho-kinases in the adhesion and
morphological properties of melanoma cells
To clarify the role of Rho/ROCK signaling in the
formation of brain metastases, we investigated the
effect of the inhibition of ROCK on the attachment of
melanoma cells to monolayers of cerebral endothelial
cells. A2058 melanoma cells were seeded onto
hCMEC/D3 (D3) endothelial monolayers in the presence
or absence of 10 lM Y27632 for 90 min. Inhibition of
ROCK led to a significant increase in the number of
melanoma cells attached to the endothelium (Fig-
ure 1A). In the absence of the endothelial monolayer,
the Y27632-induced increase in the number of A2058
cells attached to collagen was also significant, but less
pronounced. Similar changes were observed using B16/
F10 melanoma cells.
In control conditions, the ratio of elongated versus
rounded melanoma cells attached to the endothelium
was 1.33, while in the presence of Y27632, a significant
shift to the elongated morphology was observed (Fig-
ure 1A). Accordingly, Y27632 induced a significant
increase in the average area of melanoma cells attached
to the brain endothelium (Figure 1B). Consequently, the
total area of the endothelial monolayer covered by
melanoma cells increased by approximately 4.5-fold in
the presence of Y27632.
Attachment of melanoma cells to the brain endothe-
lium was also potentiated by another ROCK inhibitor,
fasudil, while the Rac inhibitor EHT1864 was able to parry
the effects of Y27632 on the attachment of melanoma
cells (Figure 2).
To investigate the morphological changes induced by
ROCK inhibition, melanoma cells were seeded onto
collagen-coated coverslips in the presence or absence
of Y27632. At 90 min after plating, the majority of both
types of melanoma cells had a rounded morphology with
several membrane blebs. Inhibition of ROCK resulted in a
switch to an elongated, fibroblastoid cell morphology
with large actin-rich protrusions, and several filopodia
(Figure 3A). Moreover, the ROCK inhibitor Y27632
increased the proteolytic activity of melanoma cells,
which was abolished by the Rac inhibitor EHT1864
(Figure 3B). These suggest that inhibition of ROCK
induces a shift of melanoma cells to the mesenchymal
type of morphology.
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Effect of Y27632 on the adhesion forces between
melanoma cells and endothelial cells
As a next step, we investigated whether the increased
number of attached melanoma cells to the endothelium
correlates with an increase in the adhesion forces
between individual melanoma cells and endothelial cells.
We attached melanoma cells to functionalized tipless
AFM cantilevers and quantified the total unbinding force
(adhesion) between the melanoma cell and endothelial
cells. When a loading force of 2 nN was applied the total
adhesion force was of 200 pN in control conditions. We
found that inhibition of ROCK led to an increase in the
total unbinding force between melanoma and endothelial
cells, reaching an approximately 2.5-fold value after
45 min (Figure 4A). Initially, the size and later the number
of individual unbinding events seemed to increase
(Figure 4B, C).
Role of adhesion molecules in the interaction of
melanoma and brain endothelial cells
The pronounced increase in the number of melanoma
cells attaching to the brain endothelium and the signif-
icant increase in the adhesion forces between the two
cell types prompted us to test the changes in the
expression of adhesion molecules in the presence of
Y27632. The expression of integrin subunits and MCAM
in melanoma cells was assessed using real-time PCR.
No difference in the mRNA expression of integrin aM, av,
a4, b1, b2, b3, and MCAM was observed between
control and Y27632-treated A2058 cells (Figure S1A).
The aL subunit was not expressed. Expression of N-
cadherin was tested using Western blot in A2058 and
B16/F10 melanoma cells. No change in the expression
of N-cadherin was seen after Y27632 treatment (Figure
S1B).
Expression and localization of ICAM-1, ICAM-2, VCAM-
1, PECAM-1, and CD99 in brain endothelial cells were
analyzed by immunofluorescence staining. ICAM-1,
VCAM-1, and E-selectin were not significantly expressed
in control brain endothelial cells, but could be induced by
TNF-a or LPS treatment. However, neither Y27632,
A2058, nor A2058-conditioned medium induced the
expression of ICAM-1, VCAM-1, or E-selectin. ICAM-2,
PECAM-1, and CD99 were present on control endothelial
cells; however, their expression was not significantly
influenced by Y27632 treatment, addition of A2058 cells
or A2058-conditioned medium (Figure S2).
Figure 2. 26Attachment of melanoma cells to brain endothelial cells in
the presence and absence of Y27632, fasudil, and EHT1864.
Fluorescently labeled A2058 melanoma cells were plated onto
confluent D3 monolayers and left for 90 min. After washing of non-
adherent cells, attached melanoma cells were counted. Results are
expressed as% control and given as mean  SD. N = 3,
* = P < 0.05 compared with control, † = P < 0.05 compared with
Y27632 + EHT1864-treated cells and ‡ = P < 0.05 compared with
fasudil + EHT1864-treated cells, as assessed by ANOVA and
Bonferroni’s post hoc test.
A
B
Figure 1. 25Attachment of melanoma cells to brain endothelial cells in
the presence and absence of Y27632. Fluorescently labeled A2058
melanoma cells were plated onto confluent D3 monolayers and left
for 90 min. After washing of non-adherent cells, attached melanoma
cells were counted. (A) Average area of single melanoma cells
attached to the brain endothelium was measured using the IMAGE
PROPLUS software. (B) Results are expressed as% control and given as
mean  SD. N = 3, *** = P < 0.0005, * = P < 0.05 as assessed by
Student’s t-test.
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We have also tested the effect of heparin – an
inhibitor of selectin- and integrin-mediated cell-cell inter-
action – on the Y-27632-induced adhesion of melanoma
cells to CECs. In control conditions (i.e. when no
Y27632 was added), pretreatment with heparin of either
melanoma or endothelial cells had no significant effect
on the number of attached cells after 90 min. Pretreat-
ment of melanoma cells with heparin did not influence
the Y-27632-enhanced adhesion of melanoma cells.
However, pretreatment of endothelial cells reduced the
number of attached melanoma cells to the control level
(Figure 5).
Effect of ROCK inhibition on the transmigration of
melanoma cells through CECs
To test whether the increase in the number of melanoma
cells attached to the endothelium is accompanied by an
increase in the number of transmigrating melanoma cells,
we cultured cerebral endothelial cells on filter inserts with
pore size of 8 lm to allow migratory cells to reach the
bottom of the filter. In response to ROCK inhibition, the
number of melanoma cells performing transendothelial
migration increased significantly by 2.75- or 2.11-fold in
case of A2058 melanoma cells treated with Y27632 and
fasudil, respectively, and by 5.60-fold in case of B16/F10
melanoma cells treated with Y27632 (Figure 6). Migration
of melanoma cells in the absence of endothelial cells was
not affected by Y27632 as assessed by the wound assay
(not shown).
Effect of Y27632 on melanoma brain metastasis
formation in vivo
We have studied the role of ROCK inhibition on mela-
noma brain metastasis formation in vivo as well. We
injected B16/F10 melanoma cells into the carotid artery of
C57/BL6 mice, some of which were additionally admin-
istered 500 lg/kg Y27632 intravenously. In control
conditions, B16/F10 was able to form mainly non-paren-
chymal (meningeal and ventricular) metastases, only
0.67  0.24 parenchymal metastasis per mouse could
be observed. However, in mice treated with Y27632, the
number of parenchymal metastases increased signifi-
cantly to 3.11  0.37 parenchymal metastasis per mouse
(Figure 7).
A
B
Figure 3. 27Effect of Y27632 on the
morphology and protease activity of
melanoma cells. (A) A2058 or B16/F10
melanoma cells were seeded onto
collagen-coated surfaces in the presence or
absence of 10 lM Y27632. After 90 min,
cells were fixed and stained with Alexa488-
labeled phalloidin. (B) A2058 melanoma
cells were preteated for 90 min with
Y27632 or Y27632 and EHT1864, then
plated onto confluent monolayers of D3
cerebral endothelial cells in serum-free
medium and left for 5 h. Cells were lysed in
Triton X-114 containing buffer. Samples
were electrophoresed in non-denaturing
conditions, and the gels were incubated in
EDTA-containing buffer for 2 days.
Proteolytic bands of culture media were
visualized by Coomassie blue staining.
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Role of melanoma versus endothelial Rho/ROCK
signaling in the transendothelial migration of
melanoma cells
As Y27632 and fasudil are reversible inhibitors, we could
not use them to differentiate between the role of Rho/
ROCK in endothelial and melanoma cells. Therefore, we
pretreated melanoma or endothelial cells with the irre-
versible Rho inhibitor CT04 and performed transmigration
experiments (Figure 8). Pretreatment of endothelial cells
with CT04 had no effect on the number of melanoma
cells migrated through the endothelial monolayer. On the
other hand, pretreatment of melanoma cells with CT04
induced a significant increase in the number of melanoma
cells migrating from the apical to the basolateral side of
the endothelium. The increase was 1.51-fold in case of
A2058 cells and 2.43-fold in case of B16/F10 cells. This
suggests that inhibition of the Rho/ROCK pathway in
melanoma, but not in brain endothelial cells induces a
significant increase in the number of melanoma cells
migrating through the endothelium. Moreover, silencing
of ROCK-I and ROCK-II genes in melanoma cells signif-
icantly increased their adhesion to the brain endothelium
(Figure 9), further supporting the role of the Rho/ROCK
pathway in melanoma cells in the interaction between
melanoma cells and brain endothelial cells. Our results
A
B CFigure 4. 28Measurement of melanoma-
endothelial adhesion force using AFM.
Fluorescently labeled A2058 melanoma
cells were attached to functionalized tipless
AFM cantilevers and pressed against a D3
endothelial layer. The adhesion force was
quantified as described in the Methods. At
T = 0, fresh medium was added containing
or not 10 lM Y27632. (A) total adhesion
force, (B) number of ruptures, (C) size of
ruptures. Results are expressed as%
control and given as mean  SD, N = 5.
Figure 5.29 Influence of heparin on the attachment of melanoma cells
to brain endothelial cells. Fluorescently labeled A2058 melanoma
cells were plated onto confluent D3 monolayers and left for 90 min.
When indicated, melanoma or endothelial cells were pretreated with
5 mg/ml heparin for 90 min (A2058(hep) and D3 (hep), respectively).
Results are expressed as% control and given as mean  SD. N = 3,
* = P < 0.05 compared with control, as assessed by ANOVA and
Bonferroni’s post hoc test.
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suggest that inhibition of both ROCK-I and ROCK-II is
needed to increase the adhesion of melanoma cells to the
brain endothelium, as silencing of either ROCK-I or ROCK-
II in melanoma cells induced only a slight, non-significant
increase in the adhesion rate (128.5  16.26% and
134.00  19.80%, respectively, compared with control
cells).
Discussion
Transmigration of melanoma cells through the brain
endothelium is a fundamental step in the formation of
brain metastases. Clarification of key mechanisms
involved in this process is of great importance. Here,
we have investigated the involvement of Rho/ROCK in
this phenomenon.
When inhibiting the Rho/ROCK pathway, the mesen-
chymal phenotype is induced which consists of an
elongated, fibroblastoid cell morphology with large actin-
rich protrusions and several filopodia, with increased
capacity of the cells to adhere to collagen and even more
to endothelial cells. Mesenchymal motility is dependent
on extracellular proteolysis. Previously, we and others
have shown that melanoma cells coming in contact with
brain endothelial cells are induced to release proteases
(Fazakas et al., 2011; Perides et al., 2006). We have
shown that melanoma cells coming in contact with brain
endothelial cells produce gelatinolytic serine proteases,
the amount of which increased in the presence of the
ROCK inhibitor Y27632. Therefore, it is conceivable that
the mesenchymal type of cell movement might be
superior to the ameboid type during migration of mela-
noma cells through the brain endothelium.
Using atomic force microscopy, we have measured the
melanoma-endothelial adhesion force in the absence and
presence of Y27632. This method monitors initial steps of
cell–cell interaction, before firm adhesion is established.
As described previously (Vegh et al., 2012), the total
A B
C
Figure 6. 30Role of ROCK inhibition in the
transendothelial migration of melanoma
cells. RBECs were grown until confluency
on 8 lm pore size filter inserts.
Fluorescently labeled melanoma cells (A,C)
A2058, (B) B16/F10 were plated into the
upper chamber in the presence or absence
of 10 lM Y27632 or 10 lM fasudil and left
for 5 h. Cells from the upper chamber were
removed using a cotton swab, and
melanoma cells migrated through the
endothelial cell layer and the pores of the
filter were counted. Results are expressed
as% control and given as mean  SD. (A)
N = 5, (B) N = 3, (C) N = 2,
** = P < 0.005; * = P < 0.01 as assessed
by Student’s t-test.
Figure 7.31 Effect of ROCK inhibition on parenchymal brain metastasis
formation in vivo. B16/F10 melanoma cells were injected into C57/
BL6 mice. Y27632 was administered intravenously in a dose of
500 lg/kg. After 10 days, animals were sacrificed and parenchymal
metastases were counted in the brains. Graph represents
mean  SEM, N = 6, ** = P < 0.005 as assessed by Student’s
t-test.
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adhesion force is composed of elementary forces of
roughly 20 pN size. Present as stairlike jumps on the
retraction (retrace) phase of the force curve, they corre-
spond to individual rupture events between the two cells
(insert on Figure S3B). The total adhesion force can be
characterized with the size and the number of elementary
jumps. It seems that mainly the elevation of the number
of the ruptures is responsible for the ROCK inhibitor-
induced increase in the total adhesion force; the size of
the ruptures grows only on shorter time scales.
Theoretically, the increased adhesiveness can be due
to the increased expression of adhesion molecules in
endothelial and/or melanoma cells, to the increased
affinity and/or velocity of the adhesion molecule(s), or to
the increase in the number of adhesion molecules coming
in contact with their target (i.e. increase in the contact
surface between the two cell types). Cell flattening might
result in an increase in the area of the intercellular
contact, making more surface molecules accessible.
Therefore, the ROCK inhibitor-induced morphological
changes themselves are partly responsible for the
increase in the adhesion force between melanoma and
endothelial cells.
The stronger adhesion properties associated with the
mesenchymal invasion were previously suggested to
depend on integrins. One hour treatment of scirrhous
gastric carcinoma cells with Y27632 upregulated the a3
integrin mRNA expression (Matsuoka et al., 2011). We
assessed the expression of several integrin subunits
which might play role in the adhesion of melanoma cells
to endothelial cells: aMb2 and aLb2 are ICAM receptors,
a4b1 is a VCAM-1 receptor, and avb3 is a PECAM-1
receptor (Humphries et al., 2006). We have shown that
ROCK inhibition did not influence the expression of ICAM-
1, ICAM-2, VCAM-1, and PECAM-1 in cerebral endothelial
cells. Similarly, expression of none of the integrin subun-
its tested was influenced by inhibition of ROCKs in
melanoma cells. This suggests that the ROCK-induced
increased melanoma-endothelial adhesion is not associ-
ated with changes in the expression of melanoma
integrins or endothelial CAMs.
We have observed, however, that the Y27632-depen-
dent mechanism enhancing adhesion of melanoma cells
to the brain endothelium could be blocked when
endothelial cells were pretreated with heparin. Heparin
has several biological effects besides its anticoagulant
activity. It was shown to bind to cell adhesion molecules
(P- and L-selectin, VLA-4 integrin) and to attenuate
metastasis formation (Bendas and Borsig, 2012). As the
Y27632-induced adhesion of melanoma cells was not
attenuated when melanoma cells were pretreated with
heparin, we conclude that the activation of integrins on
melanoma cells is not responsible for the increased
adhesiveness. The phenomenon might rather depend on
endothelial selectins and their ligands on melanoma cells.
Endothelial P-selectin was found to be crucial in promot-
ing metastasis formation in melanoma (Coupland et al.,
2012; Desch et al., 2012; Ludwig et al., 2004). However,
sialyl Lewis X-dependent lung colonization of B16
Figure 8. 32Role of melanoma versus
endothelial Rho/ROCK signaling in the
transendothelial migration of melanoma
cells. RBEC(CT04), A2058(CT04), and B16/
F10(CT04) represent cells pretreated with
1 lg/ml CT04 for 150 min. Transendothelial
migration was performed for 5 h. Results
are expressed as% control (no CT04
pretreatment) and given as mean  SD.
N = 2, * = P < 0.05 compared with
control, as assessed by ANOVA and
Bonferroni’s post hoc test.
Figure 9.33 Effect of ROCK-I and ROCK-II silencing on the adhesion of
melanoma cells onto brain endothelial cells. ROCK-I and ROCK-II
genes were silenced in A2058 melanoma cells with an efficiency of
49 and 63%, respectively, as assessed by real-time PCR. Melanoma
cells were fluorescently labeled and plated onto confluent D3
monolayers for 90 min. After washing of non-adherent cells,
attached melanoma cells were counted. Control = cells transfected
with a non-targeting RNA duplex. Results are expressed as% control
and given as mean  SD. N = 3, * = P < 0.05 as assessed by
Student’s t-test.
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melanoma cells was found to be dependent on a selectin-
like endothelial receptor distinct from E- or P-selectin
(Zhang et al., 2002).
Our data revealed that increased adhesion of mela-
noma cells was accompanied by an elevated rate of
transmigration and a significant increase in the number of
brain metastasis formation in vivo. Using B16/F10 murine
melanoma cells, we could observe a relatively low
number of parenchymal brain metastases, which is
consistent with literature data (Zhang et al., 2009).
Leptomeningeal and ventricular metastases were more
frequent. However – as we wanted to evaluate meta-
static cells migrated through the BBB – these were not
counted; only metastases of at least 500 lm distances
from the meninges and ventricles were considered. In
mice treated with Y27632, the number of parenchymal
metastases was still low, but significantly higher than in
control conditions, which confirms our in vitro results.
According to our results, migration of melanoma cells
through the BBB seems to depend on tumor but not on
endothelial Rho/ROCK signaling. Brain endothelial tight
junction proteins – which were shown to be involved in
the transmigration of melanoma cells (Fazakas et al.,
2011) – are linked to the actin cytoskeleton and are
influenced by ROCKs. Inhibition of Rho/ROCK signaling
has been shown to prevent Ca2+-induced junctional
disassembly in both epithelial and brain endothelial cells
(Samarin et al., 2007; Wilhelm et al., 2007). ROCK
enhances BBB permeability via disruption of tight junction
proteins in subarachnoid hemorrhage (Fujii et al., 2012),
while inhibition of ROCK was found to attenuate the HIV-
1 Tat protein-induced decrease in occludin levels in brain
endothelial cells (Xu et al., 2012). Altogether these data
indicate that inhibition of the Rho/ROCK pathway pre-
vents the disruption of the tight junctions in different
pathological conditions. Moreover, the ROCK inhibitor
Y27632 increases the transendothelial electrical resis-
tance of cerebral endothelial cells (unpublished results).
Therefore, it is not surprising that increase in the
transendothelial migration of melanoma cells is not due
to the inhibition of the Rho/ROCK pathway in endothelial
cells. However, Li et al. (Li et al., 2006) have observed
that inhibition of endothelial ROCK with Y27632 or
overexpression of a ROCK dominant-negative mutant in
endothelial cells prevents NCI-H209 small cell lung cancer
cells to migrate through a brain endothelial monolayer.
These data suggest that different tumor cell types may
activate different mechanisms during transendothelial
migration.
In conclusion, our data demonstrate that inhibition of
the Rho/ROCK pathway in melanoma cells enhances
transmigration of melanoma cells through the BBB. We
have identified the increased attachment of melanoma
cells to the brain endothelium as an underlying mecha-
nism. It may be hypothesized that this might depend on
the flattening of melanoma cells (on the morphological
level) and possibly on selectins (on the molecular level).
Our data suggest that the mesenchymal type of cell
movement (induced by ROCK inhibition) is more impor-
tant than the ameboid type during migration of melanoma
cells through the brain endothelium. This appears to have
clinical consequences, as pharmacological inhibitors of
ROCK signaling (e.g., fasudil) are emerging as potent
therapeutic agents in cerebral vasospasm and preclinical
studies are pursued for their utilization in the treatment of
cancer (reviewed in: (Street and Bryan, 2011)).
Methods
Cell culture and treatments
Interaction of melanoma cells with the brain endothelium was
studied using two human cell lines: the microvascular cerebral
endothelial cell line hCMEC/D3 and the A2058 melanoma cell line.
The murine melanoma cell line B16/F10 was used to confirm the data
obtained with human cells and in the in vivo experiments. For
transmigration experiments, primary rat brain endothelial cells
(RBECs) were used because of their superior barrier characteristics.
A detailed description of the in vitro model is presented in Fazakas
et al. (2011) and Wilhelm et al. (2011). A2058, B16/F10, and hCMEC/
D3 (abbreviated D3) were maintained as described previously
(Fazakas et al., 2011). RBECs were isolated from 2-week-old rats,
as described previously (Hutamekalin et al., 2008; Wilhelm et al.,
2007). Briefly, after removal of meninges, cerebral cortices were cut
into small pieces and digested in two steps with collagenase and
collagenase/dispase followed by centrifugation on percoll gradient.
Isolated microvessels were plated on fibronectin/collagen-coated
dishes. Endothelial cells growing out of the microvessels were
cultured in DMEM/F12 (Life Technologies 3), 10% plasma-derived
serum (PDS, First Link), and growth factors. In the first 2 days, 4 lg/
ml puromycin was added to remove contaminating cells.
Y27632 (Tocris) and fasudil (Santa Cruz 4) (ROCK-I and ROCK-II
inhibitors)wereused in a concentration of 10 lM.Heparin (Sigma 5)was
applied in a concentration of 5 mg/ml for 90 min. The Rac inhibitor
EHT1864 (Tocris 6) was used in a concentration of 50 lM. Selective
inhibition of Rho in either RBEC or melanoma cells was performed
using CT04 (cell permeable C3 transferase exoenzyme from Clostrid-
ium botulinum inactivating the GTPases RhoA, RhoB, and RhoC;
Cytoskeleton Inc. 7) in a concentration of 1 lg/ml for 150 min.
Attachment of melanoma cells to brain endothelial
cells
Brain endothelial cells were grown until confluency in 24-well plates.
Melanoma cells were fluorescently labeled using Oregon Green 488
carboxylic acid diacetate succinimidyl ester (abbreviated OG; Life
Technologies) using the protocol supplied by themanufacturer. A total
of 5 9 104 melanoma cells/well were loaded onto the endothelial
monolayer in serum-free medium and left for 90 min. After washing,
cells were fixed using ethanol/acetic acid (95/5) at 20°C for 5 min.
Melanoma cells attached to endothelial cells were photographed and
counted using the IMAGE-PRO PLUS software (Media Cybernetics 8).
Phalloidin staining of the actin cytoskeleton
Cells were fixed with 4% formaldehyde and permeabilized using
acetone at 20°C for 10 min. After blocking, cells were stained with
Alexa488-phalloidin (Life Technologies). Mounting was performed in
antifading embedding medium (Biomeda 9), and the distribution of the
signal was studied using a Nikon Eclipse TE2000U photomicroscope
with epifluorescent capabilities connected to a digital camera (Spot
RT KE).
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Detection of gelatinolytic serine proteases
D3 cells were grown in 12-well plates. A total of 2 9 105 A2058
melanoma cells were plated onto the endothelial monolayer in
serum-free medium and left for 5 h. Culture media were collected,
clarified by centrifugation at 10 000 9 g for 10 min on 4°C, and
prepared in mercaptoethanol-free Laemmli buffer. Samples were
electrophoresed under non-denaturing conditions in a polyacrylamide
gel containing 1.5 mg/ml gelatin. Gels were washed two times in
2.5% Triton X-100 and two times in water and incubated for 2 days at
37°C in a buffer containing 50 mM Tris pH = 7.4, 0.2 M NaCl, and
5 mM EDTA. Gels were stained with Coomassie BBR-250 for 20 min
and destained using 10% methanol and 10% acetic acid until the
gelatinolytic bands became visible.
Measurement of adhesion forces between melanoma
and endothelial cells using atomic force microscopy
(AFM)
Instrumentation
Experiments were performed with an Asylum MFP-3D-type atomic
force microscope (Asylum Research10 ), having an Axiovert 200
microscope as a support, and the MFP-3D Xop driver program,
written in Igor Pro software (v. 6.22A; Wavemetrics11 ). Silicon nitride
tipless cantilevers were used (MikroMasch12 ). Their spring constant
was defined by thermal calibration method (Hutter and Benchhoefer,
1993), giving an average of 30 pN/nm. Cantilevers were functional-
ized with a multilayer build-up, as follows: overnight incubation with
biotinylated-BSA, 15 min with streptavidin, 1–2 min with biotinylated
Concanavalin-A (Vegh et al., 2012; Zhang et al., 2006).
Experimental setup
Of 103 OG-labeled A2058 cells were placed into a 10 cm2 culture
dish containing an approximately 2 cm2 area of confluent D3 culture
in the middle of the dish. Force measurements (see below) were
performed in Leibovitz L-15 medium (Sigma). After 25 min, the
medium was replaced with fresh Leibovitz L-15 medium or one
containing 10 lM Y27632 (T = 0). Force measurements were
continued for 90 min from this time point.
Force measurements
Immediately after addition of melanoma cells into the endothelial cell-
containing culture dish, before the attachment of the tumor cells to the
endothelium or the surface of the dish, a single melanoma cell was
brought into contact with the very end of the cantilever to achieve the
attachment between them. The position of the melanoma cell on the
cantilever has been monitored continuously during the experiment,
and no considerable change occurred. The melanoma cell-containing
cantilever was brought in contact with the endothelial monolayer
(Figure S3A) with a frequency of 0.033 Hz. The travel speed of the ‘cell
probe’ was set to 2 lm/s both for lowering (trace) and for pulling back
(retrace). The total loading force applied was 2 nN. The intercellular
adhesion forces were determined from the retrace curves by calcu-
lating the relative level difference between the maximal downward
deflection of the cantilever and its alignment after total unbinding
(Figure S3B). As described previously (Vegh et al., 2012), the total
adhesion force consists of elementary forces, which present as
stairlike jumps on the retraction (retrace) phase of the force curve
(Figure S3B). A homemade MATLAB (MathWorks13 ) routine was devel-
oped to extract total adhesion force values, and statistics to quantify
the number and average size of stairlike jumps. Individual jumps on
retract curves were identified as the level difference between two
adjacent points passing a threshold. Twofold of the standard deviation
taken from the last 50 points of each curve was given as threshold.
Real-time PCR
Total RNA was isolated from untreated A2058 cells or cells treated
with Y27632 for 90 min using TRIzol reagent (Life Technologies)
following the manufacturer’s recommendations. RNA was tran-
scribed into cDNA using the SuperScript III reverse transcription kit
(Life Technologies). The amplification was performed on a BioRad
iQ5 instrument using Maxima SYBR Green Mix (Fermentas 14) under
the following conditions: 40 cycles of 95°C for 15 s, 56°C for 30 s,
72°C for 30 s. The primer pairs used for amplification are summarized
in Supplementary Table 1. Determination of threshold cycles and
quantitation was performed using the software of the instrument.
Western blot analysis
Cells were harvested in ice-cold RIPA buffer. Protein concentration
was measured using the BCA assay (Pierce 15). Proteins were electro-
phoresed and blotted onto PVDF (Millipore 16) membranes. After
blocking, anti-N-cadherin (Transduction Laboratories 17) and anti-b-actin
(Sigma) primary antibodies were used. Secondary antibodies were
from Amersham. The immunoreaction was visualized using the
Immobilon Western Chemiluminescent HRP Substrate (Millipore) on
X-ray film (Agfa 18).
Immunofluorescence staining of adhesion molecules
D3 cells were cultured until confluency in 96-well plates. Cells were
treated with 1 lg/ml LPS or 10 ng/ml TNF-a for 6 h. A total of 104
A2058 cells or A2058-conditioned media were applied for 90 min.
Cells were fixed with methanol/acetone at 20°C for 5 min, then
rehydrated in Tris-buffered saline containing 1% BSA (TBS-BSA) and
stained with anti-adhesion molecule (ICAM-1, ICAM-2, VCAM-1, E-
Selectin, PECAM-1, and CD99) antibodies (Bender Med Systems 19)
followed by rabbit anti-goat Alexa568 (in case of CD99) or goat anti-
mouse Alexa568 (all the other adhesion molecules) secondary
antibodies. Alexa-labeled secondary antibodies were purchased from
Life Technologies. Images were recorded by Olympus IX-81 fluores-
cence microscope equipped with XM-10 camera.
Transmigration of melanoma cells through brain
endothelial monolayers
Transmigration experiments were performed as described previously
(Fazakas et al., 2011; Wilhelm et al., 2011). Briefly, primary RBECs
were passed onto fibronectin/collagen-coated 8 lm pore size filter
inserts (Millipore). After reaching confluency, endothelial cells were
supplemented with 550 nM hydrocortisone, 250 lM CPT-cAMP
(Sigma), and 17.5 lM Ro 20-1724 (Sigma) from the apical side and
astrocyte-conditioned medium from the basolateral side for 24 h.
Then, 105 OG-labeled melanoma cells were plated onto the
endothelial monolayer in serum-free medium. The lower compart-
ment was loaded with serum-free medium containing 100 lg/ml
type I collagen. Cells were left for 5 h, followed by fixation with
ethanol/acetic acid. Cells from the upper compartment were
removed with a cotton swab, and melanoma cells migrated through
the endothelial monolayer and the pores of the filter were counted.
Evaluation of brain metastasis formation in vivo
Seven- to-10-week-old C57BL/6 male mice were anesthetized with
Avertin (Fluka) administered intraperitoneally (30 mg/100 g body
weight in a volume of 0.35 ml). A total of 106 B16/F10 melanoma
cells were injected in 200 ll Ringer-HEPES solution into the right
common carotid artery using a syringe with a 30-gauge needle.
Following inoculation of tumor cells, 500 lg/kg Y27632 was admin-
istered intravenously to some animals. After 10 days, animals were
sacrificed (terminal anesthesia with Avertin), transcardially perfused
with phosphate-buffered saline (PBS, 10 mM, pH = 7.4), followed by
ª 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd 9
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3.5% paraformaldehyde (Sigma) in PBS. Brains were removed and
placed into the same fixative overnight at 4°C. After post-fixation,
brains were cryoprotected in 30% sucrose (in 10 mM PBS) for at
least 2 days at 4°C. Fifty micrometer cryosections were prepared,
and melanotic lesions were counted. Only parenchymal metastases
(at a distance of at least 500 lm from the meninges and ventricles)
were considered. All mice were housed and treated in accordance
with widely accepted standards, and the protocols were approved by
the institutional care and the regional committee for animal research.
Specific knockdown of ROCK-I and ROCK-II by RNA
interference
StealthTM20 siRNA duplex oligoribonucleotides were designed using
Life Technologies BLOCK-iTTMRNAi designer and were purchased
from Life Technologies. The sequences used are summarized in
Supplementary Table 2. A2058 cells were plated at 50% confluency.
Transfection of oligonucleotides was performed in Opti-MEM
medium (Life Technologies) containing 20 nM RNA and Dharma-
FECT 4 transfection reagent (Thermo Scientific21 ) following the
manufacturer’s instructions. After 8 h, the medium was changed to
regular culture medium. To increase the efficiency, a second
transfection was performed the following day. Cells were used
24 h after the second transfection. At the same time, transfection
efficiency was analyzed by real-time PCR.
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11 AUTHOR: Please give address information for Wavemetrics: town, state (if
applicable), and country.
12 AUTHOR: Please give address information for MikroMasch: town, state (if
applicable), and country.
13 AUTHOR: Please give address information for MathWorks: town, state (if
applicable), and country.
14 AUTHOR: Please give address information for Fermentas: town, state (if
applicable), and country.
15 AUTHOR: Please give address information for Pierce: town, state (if
applicable), and country.
16 AUTHOR: Please give address information for Millipore: town, state (if
applicable), and country.
17 AUTHOR: Please give address information for Transduction Laboratories:
town, state (if applicable), and country.
18 AUTHOR: Please give address information for Agfa: town, state (if applica-
ble), and country.
19 AUTHOR: Please give address information for Bender Med Systems: town,
state (if applicable), and country.
20 AUTHOR: Please check and suggest whether the phrase “ and were” can be
changed to “which was” for clarity in the sentence “StealthTM siRNA duplex
… Life Technologies.”
21 AUTHOR: Please give address information for Thermo Scientific: town, state
(if applicable), and country.
22 AUTHOR: Guezguez et al. (2007) has not been cited in the text. Please
indicate where it should be cited; or delete from the Reference List.
23 AUTHOR: Kozlova et al. (2004) has not been cited in the text. Please indicate
where it should be cited; or delete from the Reference List.
24 AUTHOR: Metlapally et al. (2006) has not been cited in the text. Please
indicate where it should be cited; or delete from the Reference List.
25 AUTHOR: Figure 1 has been saved at a low resolution of 157 dpi. Please
resupply at 600 dpi. Check required artwork specifications at http://
authorservices.wiley.com/bauthor/illustration.asp.
26 AUTHOR: Figure 2 has been saved at a low resolution of 168 dpi. Please
resupply at 600 dpi. Check required artwork specifications at http://
authorservices.wiley.com/bauthor/illustration.asp.
27 AUTHOR: Figure 3 has been saved at a low resolution of 128 dpi. Please
resupply at 600 dpi. Check required artwork specifications at http://
authorservices.wiley.com/bauthor/illustration.asp.
28 AUTHOR: Figure 4 has been saved at a low resolution of 155 dpi. Please
resupply at 600 dpi. Check required artwork specifications at http://
authorservices.wiley.com/bauthor/illustration.asp.
29 AUTHOR: Figure 5 has been saved at a low resolution of 183 dpi. Please
resupply at 600 dpi. Check required artwork specifications at http://
authorservices.wiley.com/bauthor/illustration.asp.
30 AUTHOR: Figure 6 has been saved at a low resolution of 151 dpi. Please
resupply at 600 dpi. Check required artwork specifications at http://
authorservices.wiley.com/bauthor/illustration.asp.
31 AUTHOR: Figure 7 has been saved at a low resolution of 156 dpi. Please
resupply at 600 dpi. Check required artwork specifications at http://
authorservices.wiley.com/bauthor/illustration.asp.
32 AUTHOR: Figure 8 has been saved at a low resolution of 158 dpi. Please
resupply at 600 dpi. Check required artwork specifications at http://
authorservices.wiley.com/bauthor/illustration.asp.
33 AUTHOR: Figure 9 has been saved at a low resolution of 138 dpi. Please
resupply at 600 dpi. Check required artwork specifications at http://
authorservices.wiley.com/bauthor/illustration.asp.
 USING e-ANNOTATION TOOLS FOR ELECTRONIC PROOF CORRECTION  
 
Required software to e-Annotate PDFs: Adobe Acrobat Professional or Adobe Reader (version 8.0 or 
above). (Note that this document uses screenshots from Adobe Reader X) 
The latest version of Acrobat Reader can be downloaded for free at: http://get.adobe.com/reader/ 
 
Once you have Acrobat Reader open on your computer, click on the Comment tab at the right of the toolbar:  
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Replace (Ins) Tool Î for replacing text. 
 
Strikes a line through text and opens up a text 
box where replacement text can be entered. 
How to use it 
‚ Highlight a word or sentence. 
‚ Click on the Replace (Ins) icon in the Annotations 
section. 
‚ Type the replacement text into the blue box that 
appears. 
This will open up a panel down the right side of the document. The majority of 
tools you will use for annotating your proof will be in the Annotations section, 
rkevwtgf"qrrqukvg0"YgÓxg"rkemgf"qwv"uqog"qh"vjgug"vqqnu"dgnqy< 
 
2. Strikethrough (Del) Tool Î for deleting text. 
 
Strikes a red line through text that is to be 
deleted. 
How to use it 
‚ Highlight a word or sentence. 
‚ Click on the Strikethrough (Del) icon in the 
Annotations section. 
 
 
 
3. Add note to text Tool Î for highlighting a section 
to be changed to bold or italic. 
 
Highlights text in yellow and opens up a text 
box where comments can be entered. 
How to use it 
‚ Highlight the relevant section of text. 
‚ Click on the Add note to text icon in the 
Annotations section. 
‚ Type instruction on what should be changed 
regarding the text into the yellow box that 
appears. 
4. Add sticky note Tool Î for making notes at 
specific points in the text. 
 
Marks a point in the proof where a comment 
needs to be highlighted. 
How to use it 
‚ Click on the Add sticky note icon in the 
Annotations section. 
‚ Click at the point in the proof where the comment 
should be inserted. 
‚ Type the comment into the yellow box that 
appears. 
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For further information on how to annotate proofs, click on the Help menu to reveal a list of further options: 
5. Attach File Tool Î for inserting large amounts of 
text or replacement figures. 
 
Inserts an icon linking to the attached file in the 
appropriate pace in the text. 
How to use it 
‚ Click on the Attach File icon in the Annotations 
section. 
‚ Enkem"qp"vjg"rtqqh"vq"yjgtg"{qwÓf"nkmg"vjg"cvvcejgf"
file to be linked. 
‚ Select the file to be attached from your computer 
or network. 
‚ Select the colour and type of icon that will appear 
in the proof. Click OK. 
6. Add stamp Tool Î for approving a proof if no 
corrections are required. 
 
Inserts a selected stamp onto an appropriate 
place in the proof. 
How to use it 
‚ Click on the Add stamp icon in the Annotations 
section. 
‚ Select the stamp you want to use. (The Approved 
stamp is usually available directly in the menu that 
appears). 
‚ Enkem"qp"vjg"rtqqh"yjgtg"{qwÓf"nkmg"vjg"uvcor"vq"
appear. (Where a proof is to be approved as it is, 
this would normally be on the first page). 
7. Drawing Markups Tools Î for drawing shapes, lines and freeform 
annotations on proofs and commenting on these marks. 
Allows shapes, lines and freeform annotations to be drawn on proofs and for 
comment to be made on these marks.. 
 
How to use it 
‚ Click on one of the shapes in the Drawing 
Markups section. 
‚ Click on the proof at the relevant point and 
draw the selected shape with the cursor. 
‚ To add a comment to the drawn shape, 
move the cursor over the shape until an 
arrowhead appears. 
‚ Double click on the shape and type any 
text in the red box that appears. 
